Rituximab for congenital haemophiliacs with inhibitors: A Canadian experience

Haemophilia

Volumn 12, Issue 1, 2006, Pages 7-18

  Carcao, Manuel D ^a   St Louis, J ^b   Poon, M C ^c   Grunebaum, E ^a   Lacroix, S ^d   Stain, A M ^a   Blanchette, V S ^a   Rivard, G E ^d  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d UNIVERSITY OF MONTREAL   (Canada)

Author keywords

Congenital haemophilia; Failed immune tolerance; Inhibitors; Rituximab

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; ANTIBIOTIC AGENT; DIPHENHYDRAMINE; HYDROCORTISONE; IMMUNOGLOBULIN; PARACETAMOL; PREDNISONE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; RITUXIMAB; TRANEXAMIC ACID;

ADOLESCENT; ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; CANADA; CASE REPORT; CHILD; CLINICAL PROTOCOL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; EXPERIENCE; FOLLOW UP; HEMOPHILIA A; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; INFANT; INFECTION; MALE; MUSCLE BLEEDING; PLASMAPHERESIS; PRIORITY JOURNAL; PROSTATECTOMY; SINUSITIS; TREATMENT OUTCOME;

ADOLESCENT; AGED; ANTIBODIES, MONOCLONAL; CHILD; CLINICAL PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; FACTOR VIII; HEMOPHILIA A; HUMANS; IMMUNE TOLERANCE; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; MALE; MUTATION; TREATMENT OUTCOME;

EID: 33645981947     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2005.01170.x     Document Type: Article

References (57)

1. Scandella DH. Properties of anti-factor VIII inhibitor antibodies in hemophilia A patients. Semin Thromb Hemost 2000; 26: 137-42.
2. Strauss HS, Merler E. Characterization and properties of an inhibitor of factor 8 in the plasma of patients with hemophilia A following repeated transfusions. Blood 1967; 30: 137-50.
3. Capel P, Toppet M, van Remoortel E, Fondu P. Factor VIII inhibitor in mild haemophilia. Br J Haematol 1986; 62: 786-7.
4. Hay CR. Factor VIII inhibitors in mild and moderate-severity haemophilia A. Haemophilia 1998; 4: 558-63.
5. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. N Engl J Med 1993; 328: 453-9.
6. Ehrenforth S, Kreuz W, Scharrer I et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-8.
7. Ghirardini A, Puopolo M, Chiarotti F, Mariani G. The international registry of immune tolerance: 1994 update. Vox Sang 1996; 70 (Suppl. 1): 42-46.
8. Mariani G, Ghirardini A, Bellocco R. Immune tolerance in hemophilia-principal results from the International Registry. Report of the factor VIII and IX Subcommittee. Thromb Haemost 1994; 72: 155-8.
9. Di Michele DM. Immune tolerance: A synopsis of the international experience. Haemophilia 1998; 4: 568-73.
10. DiMichele DM, Kroner BL. Analysis of the North American Immune Tolerance Registry (NAITR) 1993-1997: Current practice implications. ISTH Factor VIII/IX Subcommittee Members. Vox Sang 1999; 77 (Suppl. 1): 31-32.
11. Lenk H. The German National Immune Tolerance Registry, 1997 update. Study Group of German Haemophilia Centres. Vox Sang 1999; 77 (Suppl. 1): 28-30.
12. Robbins D, Kulkarni R, Gera R, Scott-Emuakpor AB, Bosma K, Penner JA. Successful treatment of high titer inhibitors in mild hemophilia A with avoidance of factor VIII and immunosuppressive therapy. Am J Hematol 2001; 68: 184-8.
13. Hay CR, Ludlam CA, Colvin BT et al. Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation. Thromb Haemost 1998; 79: 762-6.
14. Reff ME, Carner K, Chambers KS et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435-45.
15. Zaja F, Iacona I, Masolini P et al. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. Haematologica 2002; 87: 189-95.
16. Cheson BD. Rituximab: Clinical development and future directions. Expert Opin Biol Ther 2002; 2: 97-110.
17. Rastetter W, Molina A, White CA. Rituximab: Expanding role in therapy for lymphomas and autoimmune diseases. Annu Rev Med 2004; 55: 477-503.
18. Banchereau J, Rousset F. Human B lymphocytes: Phenotype, proliferation, and differentiation. Adv Immunol 1992; 52: 125-262.
19. Zecca M, Nobili B, Ramenghi U et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood 2003; 101: 3857-61.
20. Quartier P, Brethon B, Philippet P, Landman-Parker J, Le Deist F, Fischer A. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet 2001; 358: 1511-3.
21. Patel K, Berman J, Ferber A, Caro J. Refractory autoimmune thrombocytopenic purpura treatment with Rituximab. Am J Hematol 2001; 67: 59-60.
22. Pedersen IM, Buhl AM, Klausen P, Geisler CH, Jurlander J. The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism. Blood 2002; 99: 1314-9.
23. Maloney D, Smith B, Appelbaum F. The anti-tumor effect of monclonal anti-CD20 antibody (MAB) therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma. Blood 1996; 88: 637a.
24. McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825-33.
25. Byrd JC, Waselenko JK, Maneatis TJ et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol 1999; 17: 791-5.
26. Sharma VR, Fleming DR, Slone SP. Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab. Blood 2000; 96: 1184-6.
27. Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001; 344: 68-9.
28. Motto DG, Williams JA, Boxer LA. Rituximab for refractory childhood autoimmune hemolytic anemia. Isr Med Assoc J 2002; 4: 1006-8.
29. Gopal AK, Press OW. Clinical applications of anti-CD20 antibodies. J Lab Clin Med 1999; 134: 445-50.
30. Cook RC, Connors JM, Gascoyne RD, Fradet G, Levy RD. Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation. Lancet 1999; 354: 1698-9.
31. Bernard F, Sarran N, Margueritte G, Barneon G, Astruc J. Successful treatment of an Epstein-Barr virus-associated B-cell lymphoproliferative disease in a child with acute lymphoblastic leukemia using an anti-CD20 monoclonal antibody. Med Pediatr Oncol 2001; 36: 329-31.
32. Donaldson SS. Pediatric Hodgkin's disease-up, up, and beyond. Int J Radiat Oncol Biol Phys 2002; 54: 1-8.
33. Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001; 98: 952-7.
34. Giagounidis AA, Anhuf J, Schneider P et al. Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: A pilot study. Eur J Haematol 2002; 69: 95-100.
35. Faurschou M, Hasselbalch HC, Nielsen OJ. Sustained remission of platelet counts following monoclonal anti-CD20 antibody therapy in two cases of idiopathic autoimmune thrombocytopenia and neutropenia. Eur J Haematol 2001; 66: 408-11.
36. Perrotta A, Sunnenberg T, Scott J. Update of response to rituximab of chronic relapsing ITP. Blood 1999; 94: 82b.
37. Morfini M. Comparative pharmacokinetic studies in haemophilia. Haemophilia 2002; 8 (Suppl. 2): 30-33.
38. Hay C, Di Michele D, Mauser-Bunschoten EP. International Immune Tolerance Therapy Study. http://www.itistudy.com. 2004.
39. Wiestner A, Cho HJ, Asch AS et al. Rituximab in the treatment of acquired factor VIII inhibitors. Blood 2002; 100: 3426-8.
40. Curtin J, Misra A, Teo J, Webster B, Lammi A. Use of rituximab as an alternative strategy for the management of difficult high titre inhibitors in children with hemophilia. Haemophilia 2004; 10: 12PO30.
41. Mathias M, Khair K, Hann I, Liesner R. Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia. Br J Haematol 2004; 125: 366-8.
42. Karwal MW, Schlueter AJ, Zenk DW, Davis R. Treatment of acquired factor VIII deficiency with rituximab. Blood 2001; 98: 2232.
43. Kain S, Copeland TS, Leahy MF. Treatment of refractory autoimmune (acquired) haemophilia with anti-CD20 (rituximab). Br J Haematol 2002; 119: 578.
44. Decesare T, Kett DH, Huang H et al. Successful outcome of rituxan therapy for spontaneously acquired high titre refractory factor VIII inhibitor. Blood 2002; 100: 3897.
45. Jy W, Gagliano-DeCesare T, Kett DH et al. Life-threatening bleeding from refractory acquired FVIII inhibitor successfully treated with rituximab. Acta Haematol 2003; 109: 206-8.
46. Fischer KG, Deschler B, Lubbert M. Acquired high-titer factor VIII inhibitor: Fatal bleeding despite multimodal treatment including rituximab preceded by multiple plasmaphereses. Blood 2003; 101: 3753-4.
47. Low BG, Cohen AJ. Complete remission in high-titre acquired factor VIII inhibitor after Rituximab therapy. Blood 2003; 102: 4114.
48. Mazjs S, Li H, Lichtman SMBD et al. Successful treatment of acquired factor VIII inhibitor with Rituximab in 4 patients. Blood 2003; 102: 2955.
49. Stasi R, Brunetti M, Stipa E, Amadori S. Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood 2004; 103: 4424-8.
50. Grimley C, Dolan G. Successful treatment of acquired haemophilia unresponsive to conventional immunosuppression with Rituximab (anti-CD20 antibody). Haemophilia 2004; 10: 12PO34.
51. Riess H. Successfull treatment of refractory acquired hemophilia with the anti-CD20 antibody rituximab. Haemophilia 2004; 10: 12PO62.
52. Aggarwal A, Catlett JP. Rituximab: An anti-CD20 antibody for the treatment of chronic refractory immune thrombocytopenic purpura. South Med J 2002; 95: 1209-12.
53. Linde R, Ettingshausen CE, Voigt B, Klingebiel T, Kreuz W. First successful inhibitor elimination with a new protocol in a high responding hemophilia A patient after failure of various immune tolerance induction regimens. Blood 2001; 98: 2236a.
54. Linde R, Escuriola Ettingshausen C, Konigs C, Dunsch D, Stoll H, Kreuz W. Rituximab as a new inhibitor elimination agent in high titre inhibitor patients -a long term followup. Haemophilia 2004; 10: 12PO51.
55. Pruthi RK, Schmidet KA, Slaby JA, Hook CC, Nichols WL. Rituximab in the treatment of high titre FVIII inhibitor in congenital hemophilia A (HA). Blood 2002; 100: 3893a.
56. Medeiros BC, Geraghty S, Stabler SP. Improved response to immune tolerance therapy for factor VIII inhibitor after rituximab therapy. Blood 2002; 100: 3890a.
57. Escobar M, Kempton C, Ma A. Successful treatment of an autoantibody in congenital hemophilia with rituximab. Blood 2002; 100: 3915a.